Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8056 to 8070 of 8896 results

  1. Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

    We have withdrawn this guidance. Grünenthal has stopped marketing Lesinurad (Zurampic) for commercial reasons and its marketing authorisation has been withdrawn.

    Withdrawn guidance

  2. Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety (TA51)

    This guidance has been updated and replaced by NICE technology appraisal guidance 97.

    Withdrawn guidance

  3. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)

    This guidance has been updated and replaced by NICE technology appraisal guidance 783.

    Withdrawn guidance

  4. Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

    This guidance has been updated and replaced by NICE technology appraisal guidance 555.

    Withdrawn guidance

  5. The clinical effectiveness and cost effectiveness of insulin pump therapy (TA57)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 151.

    Withdrawn guidance

  6. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)

    This guidance has been updated and replaced by NICE technology appraisal guidance 897.

    Withdrawn guidance

  7. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Withdrawn guidance

  8. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Withdrawn guidance

  9. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

    Withdrawn guidance

  10. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

    This guidance has been updated and replaced by NICE technology appraisal guidance 780.

    Withdrawn guidance

  11. Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

    This guidance has been updated and replaced by NICE technology appraisal guidance 849.

    Withdrawn guidance

  12. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA802.

    Withdrawn guidance

  13. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    This guidance has been updated and replaced by NICE technology appraisal guidance 687.

    Withdrawn guidance

  14. Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1059.

    Withdrawn guidance

  15. Dapagliflozin with insulin for treating type 1 diabetes (TA597)

    In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.

    Withdrawn guidance